Psilocybin for cluster headaches: what the busted-cycle data show.

Author: Austin Mao, NMF.0000036 · Reviewer: pending psychiatric oversight · Last reviewed: 2026-05-10 · 8 cited studies.

Background: cluster headache, “the suicide headache”

Cluster headache affects roughly 0.1 percent of the population over a lifetime, with episodic and chronic patterns. Attacks are routinely rated 10/10 on pain scales, hence the colloquial name. Standard care includes oxygen therapy and triptans for acute attacks, with verapamil, CGRP-modulating monoclonals, and occipital nerve blocks for prevention. Many patients remain incompletely controlled.

The patient-led Clusterbusters community organized self-reported data on psilocybin and LSD use for cluster headaches in the early 2000s, prompting the academic case series and surveys cited below and, eventually, the Yale RCT program led by Schindler and colleagues.

Mechanism: hypothesized circuit involvement

Cluster headache neurobiology features trigeminovascular activation and hypothalamic involvement, demonstrated by PET imaging studies (Goadsby 2002 and successors). The serotonergic targets exploited by triptans (5-HT1B/1D agonists) suggest a candidate target for psilocybin via overlapping receptor pharmacology, alongside its 5-HT2A action.

The Karst et al. (2010) BOL-148 case series, using a non-hallucinogenic LSD analog, is the strongest published proof-of-mechanism that the cluster-abortive effect is pharmacological, not experience-driven. Sub-perceptual or low-dose pulse protocols are studied separately from full-dose protocols because the proposed pathway here is pharmacological, not the psychedelic-experience pathway invoked in depression and anxiety trials.

Clinical evidence: small but consistent signal

Safety profile specific to cluster headaches

• Triptans: risk of serotonin syndrome if combined acutely with psilocybin; wash-out is required and must be supervised. See /safety/medication-interactions.
• Verapamil: no major direct interaction signal in published literature, but cardiovascular monitoring during session is appropriate.
• Lithium and valproate (sometimes used in chronic cluster headache): caution and physician coordination required.
• Cardiovascular pre-existing conditions: psilocybin produces transient blood pressure and heart rate elevation, relative contraindication in unstable cardiac disease. See /safety/contraindications.
• Chronic vs. episodic cluster headache: the published trials and surveys distinguish these phenotypes; chronic cluster headache is a higher-bar use case for any investigational care.

Integration considerations for cluster headaches

Cluster headache is a primarily physiological condition. Integration here looks less like psycho-spiritual reflection and more like pattern tracking, a daily headache diary, an attack frequency log, careful note-taking on triggers and remissions. The useful end-state is data the patient can bring back to a neurologist.

Mood comorbidity, depression and anxiety from chronic severe pain, is common, and integration may overlap with the framings used in the depression and anxiety pages. The Clusterbusters community uses the term “busting protocol”, a pharmacological framing, not a psychedelic-experience framing.

Practitioner perspective

“Cluster headache work is a different conversation. It is primarily a neurological condition with a serotonergic answer that patients found before academia did. Our job at intake is to ask whether a Ceremonia program is the right pathway at all, or whether a referral into the Yale-led trial network or a cluster-headache-specialist neurologist is the better next step.”